about
Current and emerging therapy for celiac diseaseEngineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions.Properties of Gluten Intolerance: Gluten Structure, Evolution, Pathogenicity and Detoxification CapabilitiesThe opioid effects of gluten exorphins: asymptomatic celiac diseaseDiversity of the cultivable human gut microbiome involved in gluten metabolism: isolation of microorganisms with potential interest for coeliac disease.The present and the future in the diagnosis and management of celiac disease.The management of refractory coeliac disease.Generation of food-grade recombinant Lactobacillus casei delivering Myxococcus xanthus prolyl endopeptidase.The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity.Identification of Pseudolysin (lasB) as an Aciduric Gluten-Degrading Enzyme with High Therapeutic Potential for Celiac DiseaseExperimental Strategy to Discover Microbes with Gluten-degrading Enzyme Activities.Structural genes of wheat and barley 5-methylcytosine DNA glycosylases and their potential applications for human health.Rapid isolation of gluten-digesting bacteria from human stool and saliva by using gliadin-containing plates.Addressing proteolytic efficiency in enzymatic degradation therapy for celiac diseaseRecent advances in the development of new treatments for celiac disease.Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge.Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease.Computational design of an α-gliadin peptidaseEffect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease.A methacrylic hyaluronic acid derivative for potential application in oral treatment of celiac disease.Active DNA demethylation: mechanism and role in plant development.Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten.Cross-Talk Between Gluten, Intestinal Microbiota and Intestinal Mucosa in Celiac Disease: Recent Advances and Basis of Autoimmunity
P2860
Q27014843-2395D465-474A-41F6-AAC0-556CD79E0232Q27336477-B3EAD8D9-90E6-4026-AFEF-A87B4C383F1BQ28072666-C2968DD8-BA5E-4817-9A8C-F490AD2DB159Q28077385-334CBFEF-0C25-42E7-A422-F25D49235C1EQ31150648-918D3517-A408-4B6B-9F46-EF3FC27291E9Q34444067-B4D95FA9-9953-404E-99F6-BB408D5089E5Q34650083-E0E11F8A-2989-4222-A06E-0B1F2A44BC31Q34661417-C1ABC584-2F69-4DEF-AB07-2F633791A868Q34743085-25B3FC31-A14F-48AB-8DB5-23F26155AE71Q35610266-4D08B967-1E1A-4039-8396-C8D87C0080B0Q35769035-784F2D68-AE3B-49B6-8A91-703A4BC5711CQ36483496-0033F17A-FA66-413A-8091-D100346A4187Q37071537-316B6354-8D05-4A34-A164-5BF8E5B05029Q37144602-167F85A3-1386-49DE-ACAF-AA8B70273160Q38038684-E33E21F1-7A0B-4BE5-8024-93E317005A74Q39762024-F3529E69-4724-427B-BE19-FE1478642957Q41546021-D9162F77-38B0-46AE-BA8B-39D13C829C89Q41834564-6779FF95-2EA4-40FB-A536-2A3DEE6FDBCEQ41840254-07BB64A0-FBCA-428C-BA86-DACF0EC46ABAQ42801372-BB8955E9-FC69-4A3F-96E7-F6763190B856Q46287371-DF61CEFD-1755-4188-957A-F817106CFCF9Q46817256-2B7D4CB6-29EF-47DE-A7EB-D7BBEDFE17E0Q59137735-1FFD1AD9-E145-4E2F-AFDB-ED0E183588BE
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Oral enzyme therapy for celiac sprue.
@en
Oral enzyme therapy for celiac sprue.
@nl
type
label
Oral enzyme therapy for celiac sprue.
@en
Oral enzyme therapy for celiac sprue.
@nl
prefLabel
Oral enzyme therapy for celiac sprue.
@en
Oral enzyme therapy for celiac sprue.
@nl
P2860
P1476
Oral enzyme therapy for celiac sprue.
@en
P2093
Chaitan Khosla
Michael T Bethune
P2860
P304
P356
10.1016/B978-0-12-416039-2.00013-6
P407
P577
2012-01-01T00:00:00Z